The IBS AS Private Equity Fund is a combination fund, investing 50% in the AlpInvest Secondaries Fund VII and 50% in the AlpInvest Co-investment Fund VIII.
The complementary combination of these two funds offers IBS clients an attractive risk-return profile.
AlpInvest is a Dutch private equity house, part of the Carlyle Group. Since inception, AlpInvest has had more than $70 billion of committed capital under management across primary, secondary and co-investment private equity strategies. The fund house has a global network, extensive experience within the various private equity strategies and has built a strong track record over the years.
The AlpInvest Secondaries Fund VII is a secondary private equity fund. The fund’s strategy is to purchase fund participations from third parties. Do focus here is on buying holdings from high-quality primary private equity managers at a discount to the underlying value.
The AlpInvest Co-investment Fund VIII is a co-investment private equity fund. The fund’s strategy is to make co-investments with high-quality private equity managers. The co-investments take place in parallel with the primary private equity manager at the company level.
The prospectuses of the closed end investment funds managed by IBS Fund Management B.V. and those of the underlying master investment funds are available to unitholders upon request (in the secure section of the site and at info@ibsfm.nl).
However, these prospectuses contain only limited information on sustainability, as the funds in question were closed before the Sustainable Finance Disclosure Regulation (“SFDR”) came into force and the SFDR could not yet be taken into account.
Prospectuses of closed end investment funds managed by IBS Fund Management B.V. with a closing date after March 10, 2021 do contain the information required by the SFDR.